Medical/Pharmaceuticals
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment ofrelapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Longer-term GC012F data in relapsed/refractory multip...
2023-05-12 05:28
2480
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
SUZHOU, China, May 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatm...
2023-05-11 23:30
2580
The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)
BARCELONA, Spain, May 11, 2023 /PRNewswire/ -- Esaote, one of the world's leading manufacturers of medical diagnostic systems (specifically, ultrasound, dedicated MRI and Medical IT systems) took part in the Congress held by the European Association of Cardiovascular Imaging inBarcelona on May 10...
2023-05-11 21:27
3658
CytoMed Therapeutics to Ring Nasdaq Closing Bell
SINGAPORE, May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, will ...
2023-05-11 21:00
3695
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 11, 2023 /PRNewswire/ -- On May 8, 2023, the authoritative oncology journal, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (Title: First-in-hum...
2023-05-11 20:55
2397
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
SAN DIEGO, May 11, 2023 /PRNewswire/ -- "Today we are pleased to announce that Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI ( Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one ...
2023-05-11 18:00
2638
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) - A RARE, LIFE-THREATENING DISEASE
KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ -- In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease. ATTR-CM is caused by unstable ...
2023-05-11 16:10
3197
Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport
TOKYO, May 11, 2023 /PRNewswire/ -- Nippon Express Italia S.p.A. (hereinafter "NX Italia"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association...
2023-05-11 14:00
2667
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inf...
2023-05-11 09:00
3804
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
ROCKVILLIE, Md. and SUZHOU, China, May 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-11 08:45
4880
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196....
2023-05-10 22:57
3078
Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin
MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin. Turn Bio's...
2023-05-10 21:00
2548
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
* Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapyin Europe * IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS, May 10, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group...
2023-05-10 20:58
1960
Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting
- Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices SEOUL, South Korea, May 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer di...
2023-05-10 13:44
2458
Doceree forms an exclusive partnership with Hello Health Group to strengthen its global footprint; forays into 8 South East Asian markets
The partnership opens a first-of-its-kind service for Hello Health Group's
pharmaceutical clients,enabling them to target HCPs with precision and
efficiency
NEW DELHI, May 10, 2023 /PRNewswire/ -- Doceree
2023-05-10 11:00
3411
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ...
2023-05-10 08:00
4181
Gencurix announced Korean and Japanese cancer patients' 15-year follow-up prognostic test clinical results
SEOUL, South Korea, May 9, 2023 /PRNewswire/ -- Gencurix
2023-05-10 08:00
2724
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to ...
2023-05-09 22:57
3033
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...
2023-05-09 22:07
2621
Ubie collaborates with Google's Android platform "Health Connect (Beta)" as a launch partner in Japan
NEW YORK, May 9, 2023 /PRNewswire/ -- Ubie, Inc. (US Headquarters: 1460 Broadway,New York, Suite 10003, NY 10036; Co-Representative Directors: Yoshinori Abe and Kota Kubo; hereinafter referred to as "Ubie") has partnered with Google's Android platform, "Health Connect (Beta)," as one of the six ...
2023-05-09 21:00
2422
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
6th HIIFF Closes with Golden Coconut Award Ceremony
[Picked up by 282 media titles]
2024-12-11 22:19
Internet celeb videos fuel Hainan travel popularity surge
[Picked up by 282 media titles]
2024-12-12 22:09
Most Read
Macaronesian Stories, a moving campaign to rebuild a dream buried by La Palma's volcano in the Canary Islands
2024-12-13 22:46
5055
GoPaint Worldwide Creating Activity Lands at the HUAWEI Flagship Store Opéra in Paris
2024-12-13 23:52
4614
6th HIIFF Closes with Golden Coconut Award Ceremony
2024-12-11 22:19
4468
